Less than three weeks away: Join Global Experts at Transderm...
11-12 November 2024 in London, UK
Newsletters and Deep Dive digital magazine
11-12 November 2024 in London, UK
Excitement for mRNA therapeutics continues, as RNA technologies are awarded the Nobel Prize for the second year running.
GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.
MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas.
Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but i
Editor's Picks
Newsletters and Deep Dive
digital magazine